NCT02499380终止不适用
Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Changes in 6 Minute Walk Distance (6MWD)
研究概览
简要总结
The objective of this post-marketing study is to advance the understanding of the mechanism of action of the CE marked RePneu Coil by observing changes in lung physiology and cardiac performance in patients with emphysema treated with the RePneu Coils, when used as intended.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subjects diagnosed with emphysematous type of COPD.
- •CT scan indicates bilateral emphysema, with sufficient lung parenchyma for coil deployment (based on PneumRx CT scoring) criteria.
- •Subject has post-bronchodilator FEV1 ≤45% predicted.
- •Subject has Total Lung Capacity >100% predicted.
- •Subject has residual volume (RV) ≥175% predicted.
- •Subject has marked dyspnea scoring ≥2 on mMRC scale of 0-
- •Subject read, understood and signed the Informed Consent form.
- •Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
排除标准
- •Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation not due to dyspnea.
- •Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma.
- •Subject has severe gas exchange abnormalities as defined by:
- •PaCO2 >55 mm Hg
- •PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)
- •Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.
- •Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- •Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- •Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
- •Subject has clinically significant bronchiectasis.
- •Subject has had previous LVR surgery, lung transplantation, lobectomy or other BLVR treatment in either lung.
- •Subject has participated in studies to treat COPD using high dose radiation.
- •Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.
- •Subject is chronically taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.
- •Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
- •Subject is on any type of antiplatelet or anticoagulant therapy which cannot be stopped for seven (7) days prior to procedure.
- •Subject has a sensitivity or allergy to Nickel.
- •Subject has a known sensitivity to drugs required to perform bronchoscopy.
- •Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
- •Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow-up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
结局指标
主要结局
Changes in 6 Minute Walk Distance (6MWD)
时间窗: Baseline, 3 months post final treatment
Changes in distance traveled during a 6 minute walk test (6MWT). Initial baseline measurement was taken prior to the treatment with the RePneu coil and the second measurement was taken 3 months after final treatment of the RePneu coil. 6MWD was measured in meters.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Correlation Between the Pulmonary Function and Intrarenal Hemodynamics in 37 T2DM Patients in Early PeriodDiabetes Mellitus, Type 2NCT02798198Fourth People's Hospital of Shenyang70
已完成
不适用
Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic VolumeDiaphragmatic FunctionLung FunctionNCT01048021University of Manitoba30
已完成
不适用
Pulmonary Pathophysiology and Inflammatory Response in Patients Treated With Ecmo for Severe Respiratory FailureRespiratory Distress Syndrome, AdultRespiratory Distress Syndrome, ChildNCT01468142Karolinska University Hospital6
Unknown
不适用
Respiratory Muscle Function Changes and Effects of Chest Physiotherapy Education Interventionin Advanced Lung CancerLung CancerNCT01743586National Taiwan University Hospital102
Unknown
不适用
Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 PatientsCovid-19NCT04371679Hasselt University40